Success rates of up to 95% have been reported from the results of Phase II/III trials investigating the safety and efficacy of a single dose of acoziborole for the treatment of sleeping sickness.
Switzerland: A Phase II/III study, published in The Lancet Infectious Diseases, investigating the safety and efficacy of a single-dose acoziborole led to treatment success rates of up to 95%,.
Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa Positive Phase II/III study results.